Investor

Active Biotech is developing pharmaceutical products within medical areas where the immune defense is of significant importance like inflammatory disease and various forms of cancer.

Active Biotech’s share is listed on the NASDAQ OMX Nordic Exchange (Stockholm) since 1986 and the company has approximately 18, 700 shareholders.

Short Name
ACTI

Press Releases

Financial Reports

Latest Presentation

Redeye: Active Biotech (Intervju): Redeye pratar med vd Helén Tuvesson om nyemissionen (in Swedish)

Events and Financial Calendar

Date: February 12, 2026
Date: May 20, 2026

Helén Tuvesson

IR Contact

Phone: +46 46 19 21 56

E-mail: helen.tuvesson@activebiotech.com

Hans Kolam

IR Contact

Phone: +46 46 19 20 44

E-mail: hans.kolam@activebiotech.com